Shopping Cart 0
Cart Subtotal
AED 0

Sanofi (SAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 0

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 0

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 0

Details

Summary

Sanofi is a healthcare company that researches, develops, manufactures and markets a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women's health; and vitamins, minerals and supplements. The R&D efforts of Sanofi include working on combination drugs to increase the effectiveness of treatments and advancing the formulation of new biologics to produce medicines with precision. It has operations across Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

Sanofi (SAN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 10

List of Figures 15

Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16

Sanofi, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 17

Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18

Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 19

Sanofi, Medical Devices Deals, 2012 to YTD 2018 21

Sanofi, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 22

Sanofi, Pharmaceuticals & Healthcare, Deal Details 36

Asset Purchase 36

Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 36

Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 37

Genzyme Acquires Caprelsa from AstraZeneca 39

Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 40

Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 41

Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For USD 98.5 Million 42

Sanofi To Acquire Generic Drugs Rights From Medreich India 43

Venture Financing 44

Thermalin Raises Funds through First Tranche of Series A Preferred Financing 44

True North Therapeutics Raises USD45 Million in Series D Financing 45

True North Therapeutics Raises USD40 Million in Series C Financing 46

Portal Instruments Raises USD25 Million in Series B Financing 48

MyoKardia Raises USD46 Million in Series B Financing 49

True North Therapeutics Raises USD35 Million in Series B Financing 50

Portal Instruments Raises USD11 Million in Series A Venture Financing 51

True North Therapeutics Raises USD22 Million in Series A Venture Financing 52

Edimer Pharma Secures USD18 Million in Series B Funding 54

Ultragenyx Pharma Raises USD 75 Million In Series B Financing 55

Kahr Medical To Raise USD 2.5 Million In Venture Financing 57

Warp Drive Bio Raises USD 75 Million In Series A Venture Financing 59

Private Equity 61

Advent International Acquires Zentiva from Sanofi for USD2.37 Billion 61

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 63

Sanofi Plans to Sell Portfolio of Drugs 65

BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 67

Partnerships 68

Ablynx Exercises Option for Licensing Agreement with Vectura 68

Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 69

Dyadic International to Enter into Research Agreement with Sanofi-Aventis 70

Chengdu Pioneer Pharma Enters into Agreement with Sanofi 71

Evotec Enters into R&D Agreement with Sanofi 72

Alnylam Pharma and Sanofi Enter into Agreement 73

Innovative Targeting Solutions Enters into Research Agreement with Sanofi 74

Applied BioMath Enters into Partnership with Sanofi for Systems Pharmacology Modeling 75

AnaBios and Sanofi Enter into Agreement 76

Iontas Enters into Agreement with Sanofi 77

Sanofi to Form Partnership with Groupe Saidal and Pasteur Institute of Algeria 78

Berg Enters into Research Agreement with Sanofi 79

Applied BioMath Enters into Partnership with Sanofi 80

Sanofi Enters into Agreement with Max Delbruck Center, Charite and Berlin Institute of Health 81

Thermalin Enters into Partnership with Sanofi 82

Bioverativ Enters into Research Agreement with Bicycle Therapeutics 83

Axxam Enters into Research Agreement with Sanofi 84

AbCellera Biologics Enters into Partnership with Sanofi Pasteur 85

Ex Scientia Enters into Research and Option Agreement with Sanofi 86

Sanofi Enters into Research Agreement with Exscientia 87

Sanofi Enters into Co-Development Agreement with MedImmune 88

Sanofi Enters into Co-Promotion Agreement with Yakult Honsha 89

Enteris BioPharma Enters into Agreement with Sanofi 90

Sanofi Enters into Agreement with JHL Biotech 91

Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 92

Mymetics Enters into Research Agreement with Sanofi 93

Alnylam Pharma Enters into Agreement with Sanofi Genzyme 94

Myriad Enters into Agreement with Sanofi 95

Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 96

Protein Sciences Enters into Agreement with Biomedical Advanced Research and Development Authority 97

Sanofi Pasteur Expands R&D Agreement with Walter Reed Army Institute of Research and Bio Manguinhos and Fiocruz 98

Sanofi Enters into Co-Development Agreement with Joslin Diabetes Center 99

Sanofi Enters into Research Agreement with Ksilink 100

Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 101

Recursion Pharma Enters into Research Agreement with Genzyme 102

Hummingbird Bioscience Enters into Partnership with Sanofi 103

Protein Sciences Enters into Co-Development Agreement with Sinergium Biotech and Mundo Sano 104

Sanofi Enters into Research Agreement with DiCE Molecules 105

Sanofi Enters into Drug Discovery Agreement with University of Tokyo 106

Sanofi and Juvenile Diabetes Research Foundation Partner with Four Research Organizations 107

Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 109

X-Chem Enters into Agreement with Sanofi 110

Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 111

Sanofi Pasteur Enters into Partnership with Infectious Disease Research Institute 112

PeptiDream Enters into Discovery Agreement with Sanofi 113

Evotec Enters into Research Agreement with Sanofi 114

Regeneron Pharma Amends Co-Development Agreement with Sanofi 115

Sanofi-Aventis Extends Agreement with Medicines For Malaria Venture 117

Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 118

Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 119

NeuroVive Pharma Enters into Co-Development Agreement with Sanofi 120

Ablynx Enters into Research Agreement with Genzyme 121

Innate Pharma Enters into Agreement with Sanofi for Next Generation Antibody-Drug Conjugates 122

VBI Vaccines Enters into Research Agreement with Sanofi Pasteur 123

Schrodinger Enters into Agreement with Sanofi 124

Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 125

Regeneron Pharma Amends Co-Development Agreement with Sanofi 126

Voyager Therapeutics Enters into Development Agreement with Genzyme 127

Adimab Enters into Agreement with Sanofi for Bispecific Antibody 128

Sanofi Enters into Research Agreement with Vect-Horus 129

Catalent Pharma Enters into Co-Development Agreement with Sanofi-Aventis 130

Evotec to Enter into Co-Development Agreement with Sanofi 131

Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 133

Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 134

Apollo Hospitals Plans to Form Joint Venture with Sanofi 135

Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 136

Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 137

Sanofi Extends its Co-Development Agreement with MyoKardia 138

Sanofi Enters into Distribution Agreement with Emcure for Oncology Drugs 139

Sanofi Enters into Co-Development Agreement with Medtronic 140

Sanofi Enters into Drug Discovery Agreement with CQDM 141

Dubai Investments to Enter into Agreement with Sanofi to Promote Generics 142

Genzyme Enters Into Research Agreement With Cleveland Clinic 143

Taiwan Liposome and Ablynx Enter into Research Agreement 144

Sanofi Pasteur Enters Into Agreement With SK Chemicals For Pneumococcal Conjugate Vaccine 145

Sanofi Enters Into Agreement With UCB For Drug Discovery 146

Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 147

Smartox Biotech Enters Into Research Agreement With Sanofi For Drug Discovery 149

Sanofi Pasteur Enters into Agreement with University of Melbourne to Develop Human Vaccines 150

Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 151

Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 152

Gubra Enters into Research Collaboration with Sanofi 153

Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 154

NextBio Enters Into Agreement With Sanofi For Translational Medicine 155

Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 156

Sanofi Pasteur Enters Into Co-Development Agreement With Xiamen University For Universal Flu Vaccine 158

Oncodesign Enters Into Research Agreement With Sanofi 159

Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 160

PharmAbcine Enters Into Research Agreement With Sanofi For Antibody Drug Discovery 161

Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 162

Y-Biologics Expands Agreement with Sanofi 163

Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 164

LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea For Zemiglo 165

Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 166

Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 167

China State Institute of Pharma Enters Into Research Agreement With Sanofi 168

Sanofi Enters Into Research Agreement With Charite- Universitatsmedizin For Treatment Of Diabetes 169

Sanofi Enters Into Research Agreement With TB Alliance To Advance Treatments For Tuberculosis 170

Sanofi Enters Into Research Agreement With Oncodesign 171

LegoChem Biosciences Enters into Research Agreement with Sanofi 172

Sanofi Enters Into Research Agreement With Brigham and Womens Hospital 173

Regulus Therapeutics Expands Agreement With Sanofi-Aventis 174

Sanofi Forms Joint Venture With Hisamitsu Pharma For OTC Medications 175

Sanofi Enters Into Co-Development Agreement With Joslin Diabetes Center For Novel Diabetes Drugs 176

Sanofi Enters Into Research Agreement With Bioneer 177

Sanofi Enters Into Co-Development Agreement With Alfresa For Antiepileptic Drug 178

Sanofi Enters into Co-Development Agreement with CNRH, INRA, ASL and 3iNature 179

Centre For Genomic Regulation Enters Into Research Agreement With Sanofi 180

Centre de Regulacio Genomica Enters Into Research Agreement With Sanofi 181

Sanofi Pasteur India Enters Into Co-Marketing Agreement With Emcure Pharma For Rabies Vaccine 182

University of California Enters Into Research Agreement With Sanofi 183

Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 184

Merger 185

Sanofi Japan and Genzyme Japan Merge 185

Licensing Agreements 186

Sanofi Enters into Licensing Agreement with Revolution Medicines 186

Sanofi Pasteur Enters into Licensing Agreement with Translate Bio 187

Bioverativ Enters into Licensing Agreement with Oxford BioMedica 188

Sanofi Pasteur Enters into Licensing Agreement with SK Chemicals 189

Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 190

Sanofi Amends Licensing Agreement with Principia Biopharma 191

Sanofi Enters into Licensing Agreement with Ablynx 192

Sanofi Enters into Licensing Agreement with ImmuNext 193

Sanofi Enters into Licensing Agreement with Hanmi Pharma 194

Avanzcare Enters into Licensing Agreement with Protein Sciences 195

uniQure Enters into Licensing Agreement with Protein Sciences 196

Sanofi Enters into Licensing Agreement with Affilogic 197

IXALTIS Enters into Licensing Agreement with Sanofi 198

Orygen Biotecnologia Enters into Licensing Agreement with Protein Sciences for Flublok 199

Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 200

Sanofi Enters into Licensing Agreement with Warp Drive Bio 201

Sanofi Enters into Licensing Agreement with Innate Pharma 202

Novo Nordisk Enters into Licensing Agreement with Ablynx 203

Sanofi Amends Licensing Agreement with Lexicon Pharma 204

Sanofi Enters into Licensing Agreement with BioNTech 206

Sanofi Enters into Licensing Agreement with Ligand Pharma 207

Zai Lab Enters into Licensing Agreement with Sanofi 208

Taisho Pharma Enters into Licensing Agreement with Ablynx 209

Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 210

Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 211

Protein Sciences Enters into Licensing Agreement with Liomont for Flublok and Panblok 212

ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 213

Sanofi Enters into Licensing Agreement with Immune Design 214

CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 215

Sanofi Enters into Licensing Agreement with Eli Lilly for Cialis 216

Oxford BioMedica Amends Licensing Agreement With Sanofi 218

Merck Expands Licensing Agreement with Ablynx 219

Ablynx Enters Into Licensing Agreement With Eddingpharm 221

Regulus Therapeutics Amends Licensing Agreement With Sanofi 223

Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 224

Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 225

Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 226

Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 227

Sanofi Pasteur Expands Licensing Agreement With Vivalis 228

Sanofi Enters into Licensing Agreement with MAB Discovery 229

Sanofi Enters into Licensing Agreement with Lead Pharma for Autoimmune Diseases 230

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 231

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 232

uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 233

Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 234

Sanofi Pasteur Enters Into Licensing Agreement With ORGANOBALANCE For Saccharomyces Cerevisiae 235

Equity Offering 236

Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 236

Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 237

Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 238

Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 239

Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 241

Ablynx Amends Private Placement of Shares 242

Ablynx Raises USD1.05 Million Through Exercise of Warrants 244

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 245

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 246

Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 247

JHL Biotech Raises USD80 Million in Private Placement of Shares 248

Ablynx Raises USD82.6 Million in Private Placement of Shares 249

Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 251

Ablynx Raises USD1.4 Million upon Exercise of Warrants 252

Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 253

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 254

X4 Pharma Spin Off from Sanofi 255

Protein Sciences Raises USD0.6 Million in Private Placement of Shares 256

Ablynx Raises USD57 Million in Private Placement of Shares 257

Regulus Therapeutics Completes Private Placement Of Shares For USD 10 Million 259

Protein Sciences Raises USD8.4 Million in Private Placement of Shares 260

Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 261

Ablynx Completes Private Placement Of Shares For USD 41 Million 262

KaloBios Pharma Completes IPO For USD 70 Million 264

Debt Offering 267

Sanofi Prices Public Offering of 3.375% Notes Due 2023 for USD1 Billion 267

Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 268

Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 269

Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.54 Billion 270

Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 271

Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 272

Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 273

Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 274

Sanofi - Key Employees 346

Sanofi - Locations And Subsidiaries 348

Head Office 348

Other Locations & Subsidiaries 348

Joint Venture 362

Recent Developments 363

Strategy And Business Planning 363

Oct 02, 2018: Sanofi concludes sale of Zentiva to Advent for $2.2bn 363

Sep 13, 2018: Sanofi to refocus two global business units 364

Jul 02, 2018: Sanofi to further accelerate its scientific presence with the opening of a Global R&D Operations Hub in Chengdu, China 365

Financial Announcements 366

Nov 02, 2017: Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed 366

Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 373

Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 379

Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 381

Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 387

Corporate Communications 395

Jul 26, 2018: Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st 395

Appendix 444

Methodology 444

About GlobalData 444

Contact Us 444

Disclaimer 444


List Of Figure

List of Figures

Sanofi, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16

Sanofi, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 17

Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18

Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 19

Sanofi, Medical Devices Deals, 2012 to YTD 2018 21


List Of Table

List of Tables

Sanofi, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16

Sanofi, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 17

Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18

Sanofi, Deals By Therapy Area, 2012 to YTD 2018 19

Sanofi, Medical Devices Deals, 2012 to YTD 2018 21

Sanofi, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 22

Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 36

Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 37

Genzyme Acquires Caprelsa from AstraZeneca 39

Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 40

Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 41

Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For USD 98.5 Million 42

Sanofi To Acquire Generic Drugs Rights From Medreich India 43

Thermalin Raises Funds through First Tranche of Series A Preferred Financing 44

True North Therapeutics Raises USD45 Million in Series D Financing 45

True North Therapeutics Raises USD40 Million in Series C Financing 46

Portal Instruments Raises USD25 Million in Series B Financing 48

MyoKardia Raises USD46 Million in Series B Financing 49

True North Therapeutics Raises USD35 Million in Series B Financing 50

Portal Instruments Raises USD11 Million in Series A Venture Financing 51

True North Therapeutics Raises USD22 Million in Series A Venture Financing 52

Edimer Pharma Secures USD18 Million in Series B Funding 54

Ultragenyx Pharma Raises USD 75 Million In Series B Financing 55

Kahr Medical To Raise USD 2.5 Million In Venture Financing 57

Warp Drive Bio Raises USD 75 Million In Series A Venture Financing 59

Advent International Acquires Zentiva from Sanofi for USD2.37 Billion 61

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 63

Sanofi Plans to Sell Portfolio of Drugs 65

BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 67

Ablynx Exercises Option for Licensing Agreement with Vectura 68

Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 69

Dyadic International to Enter into Research Agreement with Sanofi-Aventis 70

Chengdu Pioneer Pharma Enters into Agreement with Sanofi 71

Evotec Enters into R&D Agreement with Sanofi 72

Alnylam Pharma and Sanofi Enter into Agreement 73

Innovative Targeting Solutions Enters into Research Agreement with Sanofi 74

Applied BioMath Enters into Partnership with Sanofi for Systems Pharmacology Modeling 75

AnaBios and Sanofi Enter into Agreement 76

Iontas Enters into Agreement with Sanofi 77

Sanofi to Form Partnership with Groupe Saidal and Pasteur Institute of Algeria 78

Berg Enters into Research Agreement with Sanofi 79

Applied BioMath Enters into Partnership with Sanofi 80

Sanofi Enters into Agreement with Max Delbruck Center, Charite and Berlin Institute of Health 81

Thermalin Enters into Partnership with Sanofi 82

Bioverativ Enters into Research Agreement with Bicycle Therapeutics 83

Axxam Enters into Research Agreement with Sanofi 84

AbCellera Biologics Enters into Partnership with Sanofi Pasteur 85

Ex Scientia Enters into Research and Option Agreement with Sanofi 86

Sanofi Enters into Research Agreement with Exscientia 87

Sanofi Enters into Co-Development Agreement with MedImmune 88

Sanofi Enters into Co-Promotion Agreement with Yakult Honsha 89

Enteris BioPharma Enters into Agreement with Sanofi 90

Sanofi Enters into Agreement with JHL Biotech 91

Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 92

Mymetics Enters into Research Agreement with Sanofi 93

Alnylam Pharma Enters into Agreement with Sanofi Genzyme 94

Myriad Enters into Agreement with Sanofi 95

Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 96

Protein Sciences Enters into Agreement with Biomedical Advanced Research and Development Authority 97

Sanofi Pasteur Expands R&D Agreement with Walter Reed Army Institute of Research and Bio Manguinhos and Fiocruz 98

Sanofi Enters into Co-Development Agreement with Joslin Diabetes Center 99

Sanofi Enters into Research Agreement with Ksilink 100

Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 101

Recursion Pharma Enters into Research Agreement with Genzyme 102

Hummingbird Bioscience Enters into Partnership with Sanofi 103

Protein Sciences Enters into Co-Development Agreement with Sinergium Biotech and Mundo Sano 104

Sanofi Enters into Research Agreement with DiCE Molecules 105

Sanofi Enters into Drug Discovery Agreement with University of Tokyo 106

Sanofi and Juvenile Diabetes Research Foundation Partner with Four Research Organizations 107

Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 109

X-Chem Enters into Agreement with Sanofi 110

Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 111

Sanofi Pasteur Enters into Partnership with Infectious Disease Research Institute 112

PeptiDream Enters into Discovery Agreement with Sanofi 113

Evotec Enters into Research Agreement with Sanofi 114

Regeneron Pharma Amends Co-Development Agreement with Sanofi 115

Sanofi-Aventis Extends Agreement with Medicines For Malaria Venture 117

Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 118

Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 119

NeuroVive Pharma Enters into Co-Development Agreement with Sanofi 120

Ablynx Enters into Research Agreement with Genzyme 121

Innate Pharma Enters into Agreement with Sanofi for Next Generation Antibody-Drug Conjugates 122

VBI Vaccines Enters into Research Agreement with Sanofi Pasteur 123

Schrodinger Enters into Agreement with Sanofi 124

Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 125

Regeneron Pharma Amends Co-Development Agreement with Sanofi 126

Voyager Therapeutics Enters into Development Agreement with Genzyme 127

Adimab Enters into Agreement with Sanofi for Bispecific Antibody 128

Sanofi Enters into Research Agreement with Vect-Horus 129

Catalent Pharma Enters into Co-Development Agreement with Sanofi-Aventis 130

Evotec to Enter into Co-Development Agreement with Sanofi 131

Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 133

Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 134

Apollo Hospitals Plans to Form Joint Venture with Sanofi 135

Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 136

Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 137

Sanofi Extends its Co-Development Agreement with MyoKardia 138

Sanofi Enters into Distribution Agreement with Emcure for Oncology Drugs 139

Sanofi Enters into Co-Development Agreement with Medtronic 140

Sanofi Enters into Drug Discovery Agreement with CQDM 141

Dubai Investments to Enter into Agreement with Sanofi to Promote Generics 142

Genzyme Enters Into Research Agreement With Cleveland Clinic 143

Taiwan Liposome and Ablynx Enter into Research Agreement 144

Sanofi Pasteur Enters Into Agreement With SK Chemicals For Pneumococcal Conjugate Vaccine 145

Sanofi Enters Into Agreement With UCB For Drug Discovery 146

Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 147

Smartox Biotech Enters Into Research Agreement With Sanofi For Drug Discovery 149

Sanofi Pasteur Enters into Agreement with University of Melbourne to Develop Human Vaccines 150

Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 151

Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 152

Gubra Enters into Research Collaboration with Sanofi 153

Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 154

NextBio Enters Into Agreement With Sanofi For Translational Medicine 155

Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 156

Sanofi Pasteur Enters Into Co-Development Agreement With Xiamen University For Universal Flu Vaccine 158

Oncodesign Enters Into Research Agreement With Sanofi 159

Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 160

PharmAbcine Enters Into Research Agreement With Sanofi For Antibody Drug Discovery 161

Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 162

Y-Biologics Expands Agreement with Sanofi 163

Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 164

LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea For Zemiglo 165

Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 166

Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 167

China State Institute of Pharma Enters Into Research Agreement With Sanofi 168

Sanofi Enters Into Research Agreement With Charite- Universitatsmedizin For Treatment Of Diabetes 169

Sanofi Enters Into Research Agreement With TB Alliance To Advance Treatments For Tuberculosis 170

Sanofi Enters Into Research Agreement With Oncodesign 171

LegoChem Biosciences Enters into Research Agreement with Sanofi 172

Sanofi Enters Into Research Agreement With Brigham and Womens Hospital 173

Regulus Therapeutics Expands Agreement With Sanofi-Aventis 174

Sanofi Forms Joint Venture With Hisamitsu Pharma For OTC Medications 175

Sanofi Enters Into Co-Development Agreement With Joslin Diabetes Center For Novel Diabetes Drugs 176

Sanofi Enters Into Research Agreement With Bioneer 177

Sanofi Enters Into Co-Development Agreement With Alfresa For Antiepileptic Drug 178

Sanofi Enters into Co-Development Agreement with CNRH, INRA, ASL and 3iNature 179

Centre For Genomic Regulation Enters Into Research Agreement With Sanofi 180

Centre de Regulacio Genomica Enters Into Research Agreement With Sanofi 181

Sanofi Pasteur India Enters Into Co-Marketing Agreement With Emcure Pharma For Rabies Vaccine 182

University of California Enters Into Research Agreement With Sanofi 183

Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 184

Sanofi Japan and Genzyme Japan Merge 185

Sanofi Enters into Licensing Agreement with Revolution Medicines 186

Sanofi Pasteur Enters into Licensing Agreement with Translate Bio 187

Bioverativ Enters into Licensing Agreement with Oxford BioMedica 188

Sanofi Pasteur Enters into Licensing Agreement with SK Chemicals 189

Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 190

Sanofi Amends Licensing Agreement with Principia Biopharma 191

Sanofi Enters into Licensing Agreement with Ablynx 192

Sanofi Enters into Licensing Agreement with ImmuNext 193

Sanofi Enters into Licensing Agreement with Hanmi Pharma 194

Avanzcare Enters into Licensing Agreement with Protein Sciences 195

uniQure Enters into Licensing Agreement with Protein Sciences 196

Sanofi Enters into Licensing Agreement with Affilogic 197

IXALTIS Enters into Licensing Agreement with Sanofi 198

Orygen Biotecnologia Enters into Licensing Agreement with Protein Sciences for Flublok 199

Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 200

Sanofi Enters into Licensing Agreement with Warp Drive Bio 201

Sanofi Enters into Licensing Agreement with Innate Pharma 202

Novo Nordisk Enters into Licensing Agreement with Ablynx 203

Sanofi Amends Licensing Agreement with Lexicon Pharma 204

Sanofi Enters into Licensing Agreement with BioNTech 206

Sanofi Enters into Licensing Agreement with Ligand Pharma 207

Zai Lab Enters into Licensing Agreement with Sanofi 208

Taisho Pharma Enters into Licensing Agreement with Ablynx 209

Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 210

Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 211

Protein Sciences Enters into Licensing Agreement with Liomont for Flublok and Panblok 212

ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 213

Sanofi Enters into Licensing Agreement with Immune Design 214

CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 215

Sanofi Enters into Licensing Agreement with Eli Lilly for Cialis 216

Oxford BioMedica Amends Licensing Agreement With Sanofi 218

Merck Expands Licensing Agreement with Ablynx 219

Ablynx Enters Into Licensing Agreement With Eddingpharm 221

Regulus Therapeutics Amends Licensing Agreement With Sanofi 223

Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 224

Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 225

Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 226

Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 227

Sanofi Pasteur Expands Licensing Agreement With Vivalis 228

Sanofi Enters into Licensing Agreement with MAB Discovery 229

Sanofi Enters into Licensing Agreement with Lead Pharma for Autoimmune Diseases 230

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 231

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 232

uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 233

Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 234

Sanofi Pasteur Enters Into Licensing Agreement With ORGANOBALANCE For Saccharomyces Cerevisiae 235

Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 236

Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 237

Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 238

Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 239

Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 241

Ablynx Amends Private Placement of Shares 242

Ablynx Raises USD1.05 Million Through Exercise of Warrants 244

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 245

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 246

Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 247

JHL Biotech Raises USD80 Million in Private Placement of Shares 248

Ablynx Raises USD82.6 Million in Private Placement of Shares 249

Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 251

Ablynx Raises USD1.4 Million upon Exercise of Warrants 252

Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 253

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 254

X4 Pharma Spin Off from Sanofi 255

Protein Sciences Raises USD0.6 Million in Private Placement of Shares 256

Ablynx Raises USD57 Million in Private Placement of Shares 257

Regulus Therapeutics Completes Private Placement Of Shares For USD 10 Million 259

Protein Sciences Raises USD8.4 Million in Private Placement of Shares 260

Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 261

Ablynx Completes Private Placement Of Shares For USD 41 Million 262

KaloBios Pharma Completes IPO For USD 70 Million 264

Sanofi Prices Public Offering of 3.375% Notes Due 2023 for USD1 Billion 267

Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 268

Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 269

Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.54 Billion 270

Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 271

Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 272

Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 273

Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 274

Sanofi Prices Public Offering of Notes Due 2027 for USD1.3 Billion 275

Sanofi Prices Public Offering of Notes Due 2020 for USD1.1 Billion 276

Sanofi Prices Public Offering of Notes Due 2022 for USD948 Million 277

Sanofi Raises USD684.07 million in Public Offering of Notes Due 2024 278

Sanofi Raises USD570 million in Public Offering of Notes Due 2019 279

Sanofi Raises USD798.08 million in Public Offering of Notes Due 2028 280

Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 281

Sanofi Prices Public Offering of 0.875% Notes Due 2021 for USD566.4 Million 282

Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 283

Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 284

Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 285

Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 286

Sanofi Prices Public Offering of Floating Rate Notes Due 2018 for USD984 Million 287

Sanofi Prices Public Offering Of Bonds Due 2023 For USD 1.35 Billion 288

Sanofi Prices Public Offering Of Bonds Due 2020 For USD 1.3 Billion 289

Sanofi Completes Public Offering Of Notes Due 2018 For USD 1.5 Billion 290

Sanofi Completes Public Offering Of Notes Due 2017 For USD 960 Million 292

Recipharm Acquires CMO Business from Sanofi for USD60.2 Million 293

Invekra Acquires Latin America Products from Sanofi 295

Partner Therapeutics Acquires Rights of Leukine from Sanofi 296

MicroPharm Acquires Equine Antivenom Immunoglobulin Products from Sanofi Pasteur 297

Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 298

INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 300

Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 301

Impact Biomedicines Acquires Rights for Fedratinib from Sanofi 303

Icagen Acquires Arizona Research Facility from Sanofi 304

Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 305

Validus Pharma and Wood Creek Capital Acquire US Rights to Several Product Lines from Sanofi-Aventis US 306

Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 307

Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 308

Ferring Pharma Acquires Ddavp from Sanofi 309

Prollenium Medical Acquires Rights to Alyria Skincare Portfolio from Sanofi Consumer Health 310

Admedus Acquires Manufacturing Facility From Genzyme Australasia 311

Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 312

Covis Pharma To Acquire US Commercialization Rights For Five Products From sanofi-aventis 313

Fareva Acquires API Production Site from Sanofi 315

Ubichem Pharma Services Acquires Manufacturing Facility In Hungary From Sanofi 316

Sanofi Acquires Ablynx for USD4.85 Billion 317

Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 319

Zentiva to Acquire Additional 18.32% Stake in Sicomed for USD70.9 Million 321

Sanofi Acquires Protein Sciences 322

Bioverativ Therapeutics Acquires True North Therapeutics 323

Eurapharma Plans to Acquire 51% Stake in Maphar 324

Medis Labs Acquires Winthrop Pharma from Sanofi 325

Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 326

Sanofi May Acquire BioMarin Pharma 327

Sanofi to Sell 4.76% Stake in Nichi-iko Pharma 328

Sanofi May Acquire PTC Therapeutics 329

Sanofi-Synthelabo Acquires 20% Stake in Apollo Sugar Clinics for USD14.6 Million 330

Dubai Investments Divests 66% Stake in Globalpharma 331

Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 332

Sofinnova Divests Its Stake In Ablynx For USD 29.4 Million 333

Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For USD 123 Million 334

Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 335

L'Oreal Plans To Sell Its Stake In Sanofi 336

Sanofi Plans To Acquire Consumer Healthcare Products Company In China 337

Sanofi Completes Acquisition Of Genfar, Generic Drugs Manufacturer 338

Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 339

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 340

Sanofi-Aventis Israel To Acquire Consumer Healthcare Products Company 342

Evotec Acquires DeveloGen For USD18 Million 343

Sanofi, Key Competitors 345

Sanofi, Key Employees 346

Sanofi, Subsidiaries 348

Sanofi, Joint Venture 362

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Sanofi, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Sanofi is a healthcare company that researches, develops, manufactures and markets a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women's health; and vitamins, minerals and supplements. The R&D efforts of Sanofi include working on combination drugs to increase the effectiveness of treatments and advancing the formulation of new biologics to produce medicines with precision. It has operations across Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

Sanofi (SAN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 10

List of Figures 15

Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16

Sanofi, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 17

Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18

Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 19

Sanofi, Medical Devices Deals, 2012 to YTD 2018 21

Sanofi, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 22

Sanofi, Pharmaceuticals & Healthcare, Deal Details 36

Asset Purchase 36

Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 36

Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 37

Genzyme Acquires Caprelsa from AstraZeneca 39

Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 40

Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 41

Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For USD 98.5 Million 42

Sanofi To Acquire Generic Drugs Rights From Medreich India 43

Venture Financing 44

Thermalin Raises Funds through First Tranche of Series A Preferred Financing 44

True North Therapeutics Raises USD45 Million in Series D Financing 45

True North Therapeutics Raises USD40 Million in Series C Financing 46

Portal Instruments Raises USD25 Million in Series B Financing 48

MyoKardia Raises USD46 Million in Series B Financing 49

True North Therapeutics Raises USD35 Million in Series B Financing 50

Portal Instruments Raises USD11 Million in Series A Venture Financing 51

True North Therapeutics Raises USD22 Million in Series A Venture Financing 52

Edimer Pharma Secures USD18 Million in Series B Funding 54

Ultragenyx Pharma Raises USD 75 Million In Series B Financing 55

Kahr Medical To Raise USD 2.5 Million In Venture Financing 57

Warp Drive Bio Raises USD 75 Million In Series A Venture Financing 59

Private Equity 61

Advent International Acquires Zentiva from Sanofi for USD2.37 Billion 61

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 63

Sanofi Plans to Sell Portfolio of Drugs 65

BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 67

Partnerships 68

Ablynx Exercises Option for Licensing Agreement with Vectura 68

Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 69

Dyadic International to Enter into Research Agreement with Sanofi-Aventis 70

Chengdu Pioneer Pharma Enters into Agreement with Sanofi 71

Evotec Enters into R&D Agreement with Sanofi 72

Alnylam Pharma and Sanofi Enter into Agreement 73

Innovative Targeting Solutions Enters into Research Agreement with Sanofi 74

Applied BioMath Enters into Partnership with Sanofi for Systems Pharmacology Modeling 75

AnaBios and Sanofi Enter into Agreement 76

Iontas Enters into Agreement with Sanofi 77

Sanofi to Form Partnership with Groupe Saidal and Pasteur Institute of Algeria 78

Berg Enters into Research Agreement with Sanofi 79

Applied BioMath Enters into Partnership with Sanofi 80

Sanofi Enters into Agreement with Max Delbruck Center, Charite and Berlin Institute of Health 81

Thermalin Enters into Partnership with Sanofi 82

Bioverativ Enters into Research Agreement with Bicycle Therapeutics 83

Axxam Enters into Research Agreement with Sanofi 84

AbCellera Biologics Enters into Partnership with Sanofi Pasteur 85

Ex Scientia Enters into Research and Option Agreement with Sanofi 86

Sanofi Enters into Research Agreement with Exscientia 87

Sanofi Enters into Co-Development Agreement with MedImmune 88

Sanofi Enters into Co-Promotion Agreement with Yakult Honsha 89

Enteris BioPharma Enters into Agreement with Sanofi 90

Sanofi Enters into Agreement with JHL Biotech 91

Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 92

Mymetics Enters into Research Agreement with Sanofi 93

Alnylam Pharma Enters into Agreement with Sanofi Genzyme 94

Myriad Enters into Agreement with Sanofi 95

Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 96

Protein Sciences Enters into Agreement with Biomedical Advanced Research and Development Authority 97

Sanofi Pasteur Expands R&D Agreement with Walter Reed Army Institute of Research and Bio Manguinhos and Fiocruz 98

Sanofi Enters into Co-Development Agreement with Joslin Diabetes Center 99

Sanofi Enters into Research Agreement with Ksilink 100

Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 101

Recursion Pharma Enters into Research Agreement with Genzyme 102

Hummingbird Bioscience Enters into Partnership with Sanofi 103

Protein Sciences Enters into Co-Development Agreement with Sinergium Biotech and Mundo Sano 104

Sanofi Enters into Research Agreement with DiCE Molecules 105

Sanofi Enters into Drug Discovery Agreement with University of Tokyo 106

Sanofi and Juvenile Diabetes Research Foundation Partner with Four Research Organizations 107

Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 109

X-Chem Enters into Agreement with Sanofi 110

Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 111

Sanofi Pasteur Enters into Partnership with Infectious Disease Research Institute 112

PeptiDream Enters into Discovery Agreement with Sanofi 113

Evotec Enters into Research Agreement with Sanofi 114

Regeneron Pharma Amends Co-Development Agreement with Sanofi 115

Sanofi-Aventis Extends Agreement with Medicines For Malaria Venture 117

Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 118

Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 119

NeuroVive Pharma Enters into Co-Development Agreement with Sanofi 120

Ablynx Enters into Research Agreement with Genzyme 121

Innate Pharma Enters into Agreement with Sanofi for Next Generation Antibody-Drug Conjugates 122

VBI Vaccines Enters into Research Agreement with Sanofi Pasteur 123

Schrodinger Enters into Agreement with Sanofi 124

Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 125

Regeneron Pharma Amends Co-Development Agreement with Sanofi 126

Voyager Therapeutics Enters into Development Agreement with Genzyme 127

Adimab Enters into Agreement with Sanofi for Bispecific Antibody 128

Sanofi Enters into Research Agreement with Vect-Horus 129

Catalent Pharma Enters into Co-Development Agreement with Sanofi-Aventis 130

Evotec to Enter into Co-Development Agreement with Sanofi 131

Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 133

Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 134

Apollo Hospitals Plans to Form Joint Venture with Sanofi 135

Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 136

Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 137

Sanofi Extends its Co-Development Agreement with MyoKardia 138

Sanofi Enters into Distribution Agreement with Emcure for Oncology Drugs 139

Sanofi Enters into Co-Development Agreement with Medtronic 140

Sanofi Enters into Drug Discovery Agreement with CQDM 141

Dubai Investments to Enter into Agreement with Sanofi to Promote Generics 142

Genzyme Enters Into Research Agreement With Cleveland Clinic 143

Taiwan Liposome and Ablynx Enter into Research Agreement 144

Sanofi Pasteur Enters Into Agreement With SK Chemicals For Pneumococcal Conjugate Vaccine 145

Sanofi Enters Into Agreement With UCB For Drug Discovery 146

Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 147

Smartox Biotech Enters Into Research Agreement With Sanofi For Drug Discovery 149

Sanofi Pasteur Enters into Agreement with University of Melbourne to Develop Human Vaccines 150

Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 151

Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 152

Gubra Enters into Research Collaboration with Sanofi 153

Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 154

NextBio Enters Into Agreement With Sanofi For Translational Medicine 155

Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 156

Sanofi Pasteur Enters Into Co-Development Agreement With Xiamen University For Universal Flu Vaccine 158

Oncodesign Enters Into Research Agreement With Sanofi 159

Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 160

PharmAbcine Enters Into Research Agreement With Sanofi For Antibody Drug Discovery 161

Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 162

Y-Biologics Expands Agreement with Sanofi 163

Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 164

LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea For Zemiglo 165

Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 166

Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 167

China State Institute of Pharma Enters Into Research Agreement With Sanofi 168

Sanofi Enters Into Research Agreement With Charite- Universitatsmedizin For Treatment Of Diabetes 169

Sanofi Enters Into Research Agreement With TB Alliance To Advance Treatments For Tuberculosis 170

Sanofi Enters Into Research Agreement With Oncodesign 171

LegoChem Biosciences Enters into Research Agreement with Sanofi 172

Sanofi Enters Into Research Agreement With Brigham and Womens Hospital 173

Regulus Therapeutics Expands Agreement With Sanofi-Aventis 174

Sanofi Forms Joint Venture With Hisamitsu Pharma For OTC Medications 175

Sanofi Enters Into Co-Development Agreement With Joslin Diabetes Center For Novel Diabetes Drugs 176

Sanofi Enters Into Research Agreement With Bioneer 177

Sanofi Enters Into Co-Development Agreement With Alfresa For Antiepileptic Drug 178

Sanofi Enters into Co-Development Agreement with CNRH, INRA, ASL and 3iNature 179

Centre For Genomic Regulation Enters Into Research Agreement With Sanofi 180

Centre de Regulacio Genomica Enters Into Research Agreement With Sanofi 181

Sanofi Pasteur India Enters Into Co-Marketing Agreement With Emcure Pharma For Rabies Vaccine 182

University of California Enters Into Research Agreement With Sanofi 183

Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 184

Merger 185

Sanofi Japan and Genzyme Japan Merge 185

Licensing Agreements 186

Sanofi Enters into Licensing Agreement with Revolution Medicines 186

Sanofi Pasteur Enters into Licensing Agreement with Translate Bio 187

Bioverativ Enters into Licensing Agreement with Oxford BioMedica 188

Sanofi Pasteur Enters into Licensing Agreement with SK Chemicals 189

Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 190

Sanofi Amends Licensing Agreement with Principia Biopharma 191

Sanofi Enters into Licensing Agreement with Ablynx 192

Sanofi Enters into Licensing Agreement with ImmuNext 193

Sanofi Enters into Licensing Agreement with Hanmi Pharma 194

Avanzcare Enters into Licensing Agreement with Protein Sciences 195

uniQure Enters into Licensing Agreement with Protein Sciences 196

Sanofi Enters into Licensing Agreement with Affilogic 197

IXALTIS Enters into Licensing Agreement with Sanofi 198

Orygen Biotecnologia Enters into Licensing Agreement with Protein Sciences for Flublok 199

Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 200

Sanofi Enters into Licensing Agreement with Warp Drive Bio 201

Sanofi Enters into Licensing Agreement with Innate Pharma 202

Novo Nordisk Enters into Licensing Agreement with Ablynx 203

Sanofi Amends Licensing Agreement with Lexicon Pharma 204

Sanofi Enters into Licensing Agreement with BioNTech 206

Sanofi Enters into Licensing Agreement with Ligand Pharma 207

Zai Lab Enters into Licensing Agreement with Sanofi 208

Taisho Pharma Enters into Licensing Agreement with Ablynx 209

Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 210

Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 211

Protein Sciences Enters into Licensing Agreement with Liomont for Flublok and Panblok 212

ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 213

Sanofi Enters into Licensing Agreement with Immune Design 214

CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 215

Sanofi Enters into Licensing Agreement with Eli Lilly for Cialis 216

Oxford BioMedica Amends Licensing Agreement With Sanofi 218

Merck Expands Licensing Agreement with Ablynx 219

Ablynx Enters Into Licensing Agreement With Eddingpharm 221

Regulus Therapeutics Amends Licensing Agreement With Sanofi 223

Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 224

Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 225

Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 226

Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 227

Sanofi Pasteur Expands Licensing Agreement With Vivalis 228

Sanofi Enters into Licensing Agreement with MAB Discovery 229

Sanofi Enters into Licensing Agreement with Lead Pharma for Autoimmune Diseases 230

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 231

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 232

uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 233

Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 234

Sanofi Pasteur Enters Into Licensing Agreement With ORGANOBALANCE For Saccharomyces Cerevisiae 235

Equity Offering 236

Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 236

Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 237

Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 238

Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 239

Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 241

Ablynx Amends Private Placement of Shares 242

Ablynx Raises USD1.05 Million Through Exercise of Warrants 244

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 245

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 246

Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 247

JHL Biotech Raises USD80 Million in Private Placement of Shares 248

Ablynx Raises USD82.6 Million in Private Placement of Shares 249

Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 251

Ablynx Raises USD1.4 Million upon Exercise of Warrants 252

Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 253

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 254

X4 Pharma Spin Off from Sanofi 255

Protein Sciences Raises USD0.6 Million in Private Placement of Shares 256

Ablynx Raises USD57 Million in Private Placement of Shares 257

Regulus Therapeutics Completes Private Placement Of Shares For USD 10 Million 259

Protein Sciences Raises USD8.4 Million in Private Placement of Shares 260

Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 261

Ablynx Completes Private Placement Of Shares For USD 41 Million 262

KaloBios Pharma Completes IPO For USD 70 Million 264

Debt Offering 267

Sanofi Prices Public Offering of 3.375% Notes Due 2023 for USD1 Billion 267

Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 268

Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 269

Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.54 Billion 270

Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 271

Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 272

Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 273

Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 274

Sanofi - Key Employees 346

Sanofi - Locations And Subsidiaries 348

Head Office 348

Other Locations & Subsidiaries 348

Joint Venture 362

Recent Developments 363

Strategy And Business Planning 363

Oct 02, 2018: Sanofi concludes sale of Zentiva to Advent for $2.2bn 363

Sep 13, 2018: Sanofi to refocus two global business units 364

Jul 02, 2018: Sanofi to further accelerate its scientific presence with the opening of a Global R&D Operations Hub in Chengdu, China 365

Financial Announcements 366

Nov 02, 2017: Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed 366

Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 373

Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 379

Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 381

Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 387

Corporate Communications 395

Jul 26, 2018: Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st 395

Appendix 444

Methodology 444

About GlobalData 444

Contact Us 444

Disclaimer 444


List Of Figure

List of Figures

Sanofi, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16

Sanofi, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 17

Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18

Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 19

Sanofi, Medical Devices Deals, 2012 to YTD 2018 21


List Of Table

List of Tables

Sanofi, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16

Sanofi, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 17

Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18

Sanofi, Deals By Therapy Area, 2012 to YTD 2018 19

Sanofi, Medical Devices Deals, 2012 to YTD 2018 21

Sanofi, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 22

Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 36

Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 37

Genzyme Acquires Caprelsa from AstraZeneca 39

Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 40

Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 41

Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For USD 98.5 Million 42

Sanofi To Acquire Generic Drugs Rights From Medreich India 43

Thermalin Raises Funds through First Tranche of Series A Preferred Financing 44

True North Therapeutics Raises USD45 Million in Series D Financing 45

True North Therapeutics Raises USD40 Million in Series C Financing 46

Portal Instruments Raises USD25 Million in Series B Financing 48

MyoKardia Raises USD46 Million in Series B Financing 49

True North Therapeutics Raises USD35 Million in Series B Financing 50

Portal Instruments Raises USD11 Million in Series A Venture Financing 51

True North Therapeutics Raises USD22 Million in Series A Venture Financing 52

Edimer Pharma Secures USD18 Million in Series B Funding 54

Ultragenyx Pharma Raises USD 75 Million In Series B Financing 55

Kahr Medical To Raise USD 2.5 Million In Venture Financing 57

Warp Drive Bio Raises USD 75 Million In Series A Venture Financing 59

Advent International Acquires Zentiva from Sanofi for USD2.37 Billion 61

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 63

Sanofi Plans to Sell Portfolio of Drugs 65

BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 67

Ablynx Exercises Option for Licensing Agreement with Vectura 68

Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 69

Dyadic International to Enter into Research Agreement with Sanofi-Aventis 70

Chengdu Pioneer Pharma Enters into Agreement with Sanofi 71

Evotec Enters into R&D Agreement with Sanofi 72

Alnylam Pharma and Sanofi Enter into Agreement 73

Innovative Targeting Solutions Enters into Research Agreement with Sanofi 74

Applied BioMath Enters into Partnership with Sanofi for Systems Pharmacology Modeling 75

AnaBios and Sanofi Enter into Agreement 76

Iontas Enters into Agreement with Sanofi 77

Sanofi to Form Partnership with Groupe Saidal and Pasteur Institute of Algeria 78

Berg Enters into Research Agreement with Sanofi 79

Applied BioMath Enters into Partnership with Sanofi 80

Sanofi Enters into Agreement with Max Delbruck Center, Charite and Berlin Institute of Health 81

Thermalin Enters into Partnership with Sanofi 82

Bioverativ Enters into Research Agreement with Bicycle Therapeutics 83

Axxam Enters into Research Agreement with Sanofi 84

AbCellera Biologics Enters into Partnership with Sanofi Pasteur 85

Ex Scientia Enters into Research and Option Agreement with Sanofi 86

Sanofi Enters into Research Agreement with Exscientia 87

Sanofi Enters into Co-Development Agreement with MedImmune 88

Sanofi Enters into Co-Promotion Agreement with Yakult Honsha 89

Enteris BioPharma Enters into Agreement with Sanofi 90

Sanofi Enters into Agreement with JHL Biotech 91

Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 92

Mymetics Enters into Research Agreement with Sanofi 93

Alnylam Pharma Enters into Agreement with Sanofi Genzyme 94

Myriad Enters into Agreement with Sanofi 95

Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 96

Protein Sciences Enters into Agreement with Biomedical Advanced Research and Development Authority 97

Sanofi Pasteur Expands R&D Agreement with Walter Reed Army Institute of Research and Bio Manguinhos and Fiocruz 98

Sanofi Enters into Co-Development Agreement with Joslin Diabetes Center 99

Sanofi Enters into Research Agreement with Ksilink 100

Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 101

Recursion Pharma Enters into Research Agreement with Genzyme 102

Hummingbird Bioscience Enters into Partnership with Sanofi 103

Protein Sciences Enters into Co-Development Agreement with Sinergium Biotech and Mundo Sano 104

Sanofi Enters into Research Agreement with DiCE Molecules 105

Sanofi Enters into Drug Discovery Agreement with University of Tokyo 106

Sanofi and Juvenile Diabetes Research Foundation Partner with Four Research Organizations 107

Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 109

X-Chem Enters into Agreement with Sanofi 110

Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 111

Sanofi Pasteur Enters into Partnership with Infectious Disease Research Institute 112

PeptiDream Enters into Discovery Agreement with Sanofi 113

Evotec Enters into Research Agreement with Sanofi 114

Regeneron Pharma Amends Co-Development Agreement with Sanofi 115

Sanofi-Aventis Extends Agreement with Medicines For Malaria Venture 117

Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 118

Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 119

NeuroVive Pharma Enters into Co-Development Agreement with Sanofi 120

Ablynx Enters into Research Agreement with Genzyme 121

Innate Pharma Enters into Agreement with Sanofi for Next Generation Antibody-Drug Conjugates 122

VBI Vaccines Enters into Research Agreement with Sanofi Pasteur 123

Schrodinger Enters into Agreement with Sanofi 124

Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 125

Regeneron Pharma Amends Co-Development Agreement with Sanofi 126

Voyager Therapeutics Enters into Development Agreement with Genzyme 127

Adimab Enters into Agreement with Sanofi for Bispecific Antibody 128

Sanofi Enters into Research Agreement with Vect-Horus 129

Catalent Pharma Enters into Co-Development Agreement with Sanofi-Aventis 130

Evotec to Enter into Co-Development Agreement with Sanofi 131

Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 133

Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 134

Apollo Hospitals Plans to Form Joint Venture with Sanofi 135

Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 136

Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 137

Sanofi Extends its Co-Development Agreement with MyoKardia 138

Sanofi Enters into Distribution Agreement with Emcure for Oncology Drugs 139

Sanofi Enters into Co-Development Agreement with Medtronic 140

Sanofi Enters into Drug Discovery Agreement with CQDM 141

Dubai Investments to Enter into Agreement with Sanofi to Promote Generics 142

Genzyme Enters Into Research Agreement With Cleveland Clinic 143

Taiwan Liposome and Ablynx Enter into Research Agreement 144

Sanofi Pasteur Enters Into Agreement With SK Chemicals For Pneumococcal Conjugate Vaccine 145

Sanofi Enters Into Agreement With UCB For Drug Discovery 146

Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 147

Smartox Biotech Enters Into Research Agreement With Sanofi For Drug Discovery 149

Sanofi Pasteur Enters into Agreement with University of Melbourne to Develop Human Vaccines 150

Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 151

Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 152

Gubra Enters into Research Collaboration with Sanofi 153

Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 154

NextBio Enters Into Agreement With Sanofi For Translational Medicine 155

Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 156

Sanofi Pasteur Enters Into Co-Development Agreement With Xiamen University For Universal Flu Vaccine 158

Oncodesign Enters Into Research Agreement With Sanofi 159

Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 160

PharmAbcine Enters Into Research Agreement With Sanofi For Antibody Drug Discovery 161

Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 162

Y-Biologics Expands Agreement with Sanofi 163

Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 164

LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea For Zemiglo 165

Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 166

Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 167

China State Institute of Pharma Enters Into Research Agreement With Sanofi 168

Sanofi Enters Into Research Agreement With Charite- Universitatsmedizin For Treatment Of Diabetes 169

Sanofi Enters Into Research Agreement With TB Alliance To Advance Treatments For Tuberculosis 170

Sanofi Enters Into Research Agreement With Oncodesign 171

LegoChem Biosciences Enters into Research Agreement with Sanofi 172

Sanofi Enters Into Research Agreement With Brigham and Womens Hospital 173

Regulus Therapeutics Expands Agreement With Sanofi-Aventis 174

Sanofi Forms Joint Venture With Hisamitsu Pharma For OTC Medications 175

Sanofi Enters Into Co-Development Agreement With Joslin Diabetes Center For Novel Diabetes Drugs 176

Sanofi Enters Into Research Agreement With Bioneer 177

Sanofi Enters Into Co-Development Agreement With Alfresa For Antiepileptic Drug 178

Sanofi Enters into Co-Development Agreement with CNRH, INRA, ASL and 3iNature 179

Centre For Genomic Regulation Enters Into Research Agreement With Sanofi 180

Centre de Regulacio Genomica Enters Into Research Agreement With Sanofi 181

Sanofi Pasteur India Enters Into Co-Marketing Agreement With Emcure Pharma For Rabies Vaccine 182

University of California Enters Into Research Agreement With Sanofi 183

Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 184

Sanofi Japan and Genzyme Japan Merge 185

Sanofi Enters into Licensing Agreement with Revolution Medicines 186

Sanofi Pasteur Enters into Licensing Agreement with Translate Bio 187

Bioverativ Enters into Licensing Agreement with Oxford BioMedica 188

Sanofi Pasteur Enters into Licensing Agreement with SK Chemicals 189

Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 190

Sanofi Amends Licensing Agreement with Principia Biopharma 191

Sanofi Enters into Licensing Agreement with Ablynx 192

Sanofi Enters into Licensing Agreement with ImmuNext 193

Sanofi Enters into Licensing Agreement with Hanmi Pharma 194

Avanzcare Enters into Licensing Agreement with Protein Sciences 195

uniQure Enters into Licensing Agreement with Protein Sciences 196

Sanofi Enters into Licensing Agreement with Affilogic 197

IXALTIS Enters into Licensing Agreement with Sanofi 198

Orygen Biotecnologia Enters into Licensing Agreement with Protein Sciences for Flublok 199

Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 200

Sanofi Enters into Licensing Agreement with Warp Drive Bio 201

Sanofi Enters into Licensing Agreement with Innate Pharma 202

Novo Nordisk Enters into Licensing Agreement with Ablynx 203

Sanofi Amends Licensing Agreement with Lexicon Pharma 204

Sanofi Enters into Licensing Agreement with BioNTech 206

Sanofi Enters into Licensing Agreement with Ligand Pharma 207

Zai Lab Enters into Licensing Agreement with Sanofi 208

Taisho Pharma Enters into Licensing Agreement with Ablynx 209

Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 210

Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 211

Protein Sciences Enters into Licensing Agreement with Liomont for Flublok and Panblok 212

ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 213

Sanofi Enters into Licensing Agreement with Immune Design 214

CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 215

Sanofi Enters into Licensing Agreement with Eli Lilly for Cialis 216

Oxford BioMedica Amends Licensing Agreement With Sanofi 218

Merck Expands Licensing Agreement with Ablynx 219

Ablynx Enters Into Licensing Agreement With Eddingpharm 221

Regulus Therapeutics Amends Licensing Agreement With Sanofi 223

Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 224

Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 225

Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 226

Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 227

Sanofi Pasteur Expands Licensing Agreement With Vivalis 228

Sanofi Enters into Licensing Agreement with MAB Discovery 229

Sanofi Enters into Licensing Agreement with Lead Pharma for Autoimmune Diseases 230

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 231

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 232

uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 233

Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 234

Sanofi Pasteur Enters Into Licensing Agreement With ORGANOBALANCE For Saccharomyces Cerevisiae 235

Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 236

Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 237

Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 238

Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 239

Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 241

Ablynx Amends Private Placement of Shares 242

Ablynx Raises USD1.05 Million Through Exercise of Warrants 244

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 245

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 246

Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 247

JHL Biotech Raises USD80 Million in Private Placement of Shares 248

Ablynx Raises USD82.6 Million in Private Placement of Shares 249

Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 251

Ablynx Raises USD1.4 Million upon Exercise of Warrants 252

Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 253

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 254

X4 Pharma Spin Off from Sanofi 255

Protein Sciences Raises USD0.6 Million in Private Placement of Shares 256

Ablynx Raises USD57 Million in Private Placement of Shares 257

Regulus Therapeutics Completes Private Placement Of Shares For USD 10 Million 259

Protein Sciences Raises USD8.4 Million in Private Placement of Shares 260

Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 261

Ablynx Completes Private Placement Of Shares For USD 41 Million 262

KaloBios Pharma Completes IPO For USD 70 Million 264

Sanofi Prices Public Offering of 3.375% Notes Due 2023 for USD1 Billion 267

Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 268

Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 269

Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.54 Billion 270

Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 271

Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 272

Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 273

Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 274

Sanofi Prices Public Offering of Notes Due 2027 for USD1.3 Billion 275

Sanofi Prices Public Offering of Notes Due 2020 for USD1.1 Billion 276

Sanofi Prices Public Offering of Notes Due 2022 for USD948 Million 277

Sanofi Raises USD684.07 million in Public Offering of Notes Due 2024 278

Sanofi Raises USD570 million in Public Offering of Notes Due 2019 279

Sanofi Raises USD798.08 million in Public Offering of Notes Due 2028 280

Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 281

Sanofi Prices Public Offering of 0.875% Notes Due 2021 for USD566.4 Million 282

Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 283

Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 284

Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 285

Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 286

Sanofi Prices Public Offering of Floating Rate Notes Due 2018 for USD984 Million 287

Sanofi Prices Public Offering Of Bonds Due 2023 For USD 1.35 Billion 288

Sanofi Prices Public Offering Of Bonds Due 2020 For USD 1.3 Billion 289

Sanofi Completes Public Offering Of Notes Due 2018 For USD 1.5 Billion 290

Sanofi Completes Public Offering Of Notes Due 2017 For USD 960 Million 292

Recipharm Acquires CMO Business from Sanofi for USD60.2 Million 293

Invekra Acquires Latin America Products from Sanofi 295

Partner Therapeutics Acquires Rights of Leukine from Sanofi 296

MicroPharm Acquires Equine Antivenom Immunoglobulin Products from Sanofi Pasteur 297

Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 298

INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 300

Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 301

Impact Biomedicines Acquires Rights for Fedratinib from Sanofi 303

Icagen Acquires Arizona Research Facility from Sanofi 304

Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 305

Validus Pharma and Wood Creek Capital Acquire US Rights to Several Product Lines from Sanofi-Aventis US 306

Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 307

Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 308

Ferring Pharma Acquires Ddavp from Sanofi 309

Prollenium Medical Acquires Rights to Alyria Skincare Portfolio from Sanofi Consumer Health 310

Admedus Acquires Manufacturing Facility From Genzyme Australasia 311

Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 312

Covis Pharma To Acquire US Commercialization Rights For Five Products From sanofi-aventis 313

Fareva Acquires API Production Site from Sanofi 315

Ubichem Pharma Services Acquires Manufacturing Facility In Hungary From Sanofi 316

Sanofi Acquires Ablynx for USD4.85 Billion 317

Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 319

Zentiva to Acquire Additional 18.32% Stake in Sicomed for USD70.9 Million 321

Sanofi Acquires Protein Sciences 322

Bioverativ Therapeutics Acquires True North Therapeutics 323

Eurapharma Plans to Acquire 51% Stake in Maphar 324

Medis Labs Acquires Winthrop Pharma from Sanofi 325

Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 326

Sanofi May Acquire BioMarin Pharma 327

Sanofi to Sell 4.76% Stake in Nichi-iko Pharma 328

Sanofi May Acquire PTC Therapeutics 329

Sanofi-Synthelabo Acquires 20% Stake in Apollo Sugar Clinics for USD14.6 Million 330

Dubai Investments Divests 66% Stake in Globalpharma 331

Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 332

Sofinnova Divests Its Stake In Ablynx For USD 29.4 Million 333

Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For USD 123 Million 334

Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 335

L'Oreal Plans To Sell Its Stake In Sanofi 336

Sanofi Plans To Acquire Consumer Healthcare Products Company In China 337

Sanofi Completes Acquisition Of Genfar, Generic Drugs Manufacturer 338

Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 339

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 340

Sanofi-Aventis Israel To Acquire Consumer Healthcare Products Company 342

Evotec Acquires DeveloGen For USD18 Million 343

Sanofi, Key Competitors 345

Sanofi, Key Employees 346

Sanofi, Subsidiaries 348

Sanofi, Joint Venture 362

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Sanofi, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.